Compare ELOX & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ELOX | COHN |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Investment Bankers/Brokers/Service |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.0M | 38.7M |
| IPO Year | 2013 | 2003 |
| Metric | ELOX | COHN |
|---|---|---|
| Price | $15.75 | $10.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 36.6K | 11.4K |
| Earning Date | N/A | 05-01-2026 |
| Dividend Yield | N/A | ★ 4.35% |
| EPS Growth | 41.67 | ★ 5537.50 |
| EPS | N/A | ★ 1.36 |
| Revenue | N/A | ★ $275,564,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.13 |
| Revenue Growth | N/A | ★ 246.19 |
| 52 Week Low | $10.00 | $9.19 |
| 52 Week High | $23.40 | $32.60 |
| Indicator | ELOX | COHN |
|---|---|---|
| Relative Strength Index (RSI) | 49.97 | 39.06 |
| Support Level | $15.21 | $10.39 |
| Resistance Level | $19.66 | $11.65 |
| Average True Range (ATR) | 2.75 | 0.33 |
| MACD | -0.29 | 0.04 |
| Stochastic Oscillator | 26.79 | 20.97 |
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.